Wikisage, the free encyclopedia of the second generation, is digital heritage
Drisapersen: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (→Links) |
||
| Line 5: | Line 5: | ||
==Links== | ==Links== | ||
[http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2019;volume=67;issue=3;spage=717;epage=723;aulast=Arora Duchenne muscular dystrophy: Still an incurable disease] | [http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2019;volume=67;issue=3;spage=717;epage=723;aulast=Arora Duchenne muscular dystrophy: Still an incurable disease] | ||
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010191/ | |||
Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study] | |||
{{refs}} | {{refs}} | ||
Revision as of 23:28, 11 September 2019
An exon skipping experimental Medicine[1] [2] PRO051/GSK2402968 is considered an orphan drug Duchenne muscular distrophy
Links
Duchenne muscular dystrophy: Still an incurable disease
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010191/ Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study]
| References: |